Hims & Hers: Subscription Health Re-Evaluated

01:24pm, Friday, 24'th Sep 2021
Hims & Hers is back to reporting impressive revenue growth near 70%.
As high-growth names start to make a comeback, investors would do well to consider this healthcare stock. Hims is likely to smash through its 30% revenue growth rate expectations in 2022.
Hims & Hers Health Inc (NYSE: HIMS) has expanded its women's health offerings by launching a D-Mannose dietary supplement powder to support urinary tract health on ForHers.com. The supplement powde

3 Stocks You'll Be Glad You Bought at These Prices

11:00am, Wednesday, 15'th Sep 2021
New companies in U.S. healthcare are bringing innovative, positive solutions to consumers.
Hims & Hers Health Inc. HIMS, +1.04% said Wednesday that its products focused on skin and haircare, sleep and sexual health will now be available on the e-commerce fashion site Revolve. Revolve Group

Revolve To Offer Hims & Hers Health Products

11:10am, Tuesday, 14'th Sep 2021
Telehealth platform Hims & Hers Health Inc (NYSE: HIMS) has announced a partnership with Revolve Group Inc (NYSE: RVLV). Revolve will add a range of health and wellness solutions from Hims & Her
All three are rapidly expanding into their own corners of America's $4 trillion per year healthcare sector.
Both grew their sales by more than 50% in their most recent quarters.
One of the most well-known NFL players is partnering with a health care company to bring awareness to men's health issues and treatment. What Happened: Tampa Bay Buccaneers tight end Rob Gronkowski ha
Hims & Hers Health Inc (NYSE: HIMS) has announced that Spencer Lee will step down as its Chief Financial Officer. Lee will lead a six-month transition plan and continue to support the company until
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers partners with Rob Gronkowski to bring awareness to men's health issues and treatment.

Time To Buy Hims & Hers

10:56am, Wednesday, 25'th Aug 2021
Hims & Hers is a consumer healthcare brand targeting young digitally native consumers and stigmatized disorders. Hims & Hers management is building a track record of strong growth, scalability, and un
The stock now trades at an all-time low. Investors are too fearful to even consider this stock. Meanwhile, Hims & Hers continues to grow at a strong rate, with impressive guidance ahead.
This stock's share price is not matching up with the company's underlying performance. Let's investigate.
New week, new price target decrease from an analyst.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE